Crizotinib was the first oral TKI molecule approved in 2011 by the FDA for metastatic NSCLC patients with ALK mutation, but almost a third of the patients had developed primary or secondary resistance within 1-2 years [71]. This evidence concerns the gene ALK and non-small cell lung carcinoma.